About Neuland Laboratories Limited



Neuland Laboratories Limited is an Indian pharmaceutical company headquartered in Hyderabad, Telangana, India. Established in 1984 by Dr. DR Rao, the company is an end-to-end solutions provider of APIs and advanced intermediates to the pharmaceutical industry. It has a global footprint in 85+ countries, and exports more than 80% of its products exports to US and Europe.


The company has a presence in 10 therapeutic categories, including cardiovascular, central nervous systems, anti-asthmatics, anti-fungal, anti-invectives, anti-ulcerants and anti-spasmodic.


The company’s major business segments comprise:

  • Active Pharmaceutical Ingredients

The company manufactures APIs for leading pharmaceutical companies worldwide via its FDA approved facilities.

  • Custom Manufacturing Solutions (CMS)
    The company manufactures products at various phases of their lifecycle via the following services:

    • Manufacturing APIs to custom specifications
    • Designing and developing manufacturing processes
    • Process optimization 
    • Filing DMFs/CMCs for APIs
    • Patent protection 

As of 31st March 2017, Neuland Laboratories had:


  • 2 US FDA and EU GMP compliant manufacturing facilities
  • A 202-person strong R&D facility with 11 development labs
  • 75 APIs across 10 therapeutic categories
  • A worldwide customer base in 85+ countries


Neuland Laboratories Ltd. is listed both on Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).


Neuland Laboratories Limited at-a-glance

  • Sales Turnover ~USD 77 million


  • (31 March 2016) (~?511.59 crores)
    • Employees 793
    • Markets Served (countries) 85+
    • Manufacturing Facilities 2
    • DMFs with US FDA 48
    • Filings with Health Canada 25
    • EUDMF Filings ~400
    • CEPs Received for Different Products 19


  • US FDA, TGA, EDQM, German Health Authority, ANVISA
  • ISO 14001 and ISO 27001
  • OHSAS 18001






*Source: https://www.neulandlabs.com



The company has not shared this information



  • 1984: Neuland Laboratories is incorporated in Hyderabad
  • 1986: Witnesses first ever API sale of salbutamol sulphate
  • 1994: Goes public with its IPO and raises capital for construction of second production facility
  • 1997: Receives its first US FDA approval
  • 1999
    • US FDA inspects Neuland’s manufacturing facilities
    • Receives certificate of suitability for Ranitidine
  • 2004: Establishes operations in North America
  • 2007: Establishes a Japan subsidiary in Tokyo
  • 2008:
    • Achieves ISMS certification
    • Unit 1 is successfully inspected by USFDA
    • Unit 1 is certified for ISO 14001 and OHSAS 18001
  • 2009:
    • Receives approval from PMDA, Japan
  • 2010: Receives certification for ISO 14001:2004 and OHSAS 18001:2007
  • 2014:
    • Enters into a Joint Business Agreement with API Corporation Japan
    • Opens new office in New Jersey, USA. Wins CMO Awards
  • 2015: Conducts 10th FDA inspection



  • Chairman and Managing Director - Dr. Davuluri Rama Mohan Rao
  • Vice-Chairman and CEO - Mr. Davuluri Sucheth Rao
  • Joint Managing Director - Mr. Davuluri Saharsh Rao
  • Non-Executive Director - Dr. Christopher M. Cimarusti
  • Independent Director - Mr. Humayun Dhanrajgir, Mr. Parampally Vasudeva Maiya, Dr. Will Gordon Mitchell ,Mrs. Bharati Rao, Ms. Nirmala Murthy





Neuland Laboratories Limited

Sanali Info Park, ‘A’ Block, Ground Floor

8-2-120/113, Road No. 2, Banjara Hills

Hyderabad, 500034

Telangana, India


Website: https://www.neulandlabs.com

Tel: +91 40 3021 1600

Fax: +91 40 3021 1602

Email: neuland@neulandlabs.com




* Indicates mandatory field.
Please wait while comments are being sent...